TNFRSF9 and cancer: Fortunately, new therapeutic modalities using 4-1BB targeted aptamers (119, 128, 140), as well as therapeutic combinations with other immuno-modulatory and traditional anti-cancer treatments, have renewed excitement for the use of 4-1BB agonists in the clinic.